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Expression of viral oncoproteins results in the loss of cell cycle checkpoint control and the accumulation of
chromosomal abnormalities. Expression of both human papillomavirus type 16 oncoproteins, E6 and E7, in
normal human fibroblasts completely dissociates p21 and proliferating cell nuclear antigen from the quarter-
nary cyclin–cyclin-dependent kinase (CDK) complexes present in normal cells, causes disruption of the cyclin
D-CDK4 complex and replacement with a CDK4-p16 complex, and leaves binary complexes of cyclin B1-CDC2
and cyclin A-CDK2 intact. These results are identical to those observed in fully transformed cells. The
expression of the individual oncoproteins dramatically affects the association of proliferating cell nuclear
antigen into the complexes while leaving the total cellular levels unaltered. Expression of low-risk human
papillomavirus has no effect on cyclin complexes. These findings provide evidence for the gross alteration of
cyclin-CDK complexes in preneoplastic cells and links this alteration to the loss of genomic stability.
The human papillomaviruses (HPVs) are associated with
tumors of the epithelial or fibroepithelial components of skin
or mucosa. Numerous clinical, epidemiological, and molecular
studies associate specific viral types with the formation of car-
cinomas of the genital and oral mucosa (68). Some HPV types
(16, 18, 31, 33, and 39) are referred to as high risk because of
their association with cervical carcinoma, while other types (6
and 11) associated with benign lesions are termed low risk.
Two viral gene products, E6 and E7, from the high-risk virus
are necessary for efficient transformation of human cells (7, 25,
41, 59). These viral oncoproteins bind a set of host cellular
proteins. The HPV type 16 (HPV16) E6 gene product binds
and aids in the degradation of p53 (52), while the E7 gene
product binds and functionally inactivates a set of cellular
proteins, including the members of the retinoblastoma protein
(Rb) tumor suppressor family (10, 41). These properties of the
HPV viral oncoproteins are shared by the oncoproteins of both
simian virus 40 [(SV40) T antigen] and adenoviruses (E1A and
E1B) (12, 56). The mechanistic effects of these protein cou-
plings on the neoplastic process are under intense investiga-
tion.
Virally transformed cells are genomically unstable, exhibit-
ing aneuploidy and chromosomal rearrangements (29). In
studies designed to address the mechanistic basis for this ob-
servation, we found that the expression of viral oncoproteins in
normal human fibroblasts (NHFs) dramatically affects cell cy-
cle control and genomic integrity (61). We expressed the E6
and E7 viral oncoproteins from the high-risk HPV16 in an
NHF strain (NHF1) that has previously been extensively char-
acterized and lacks a detectable frequency of gene amplifica-
tion. We find that NHFs expressing E6 and E7 either together
(NHFE6/E7 cells) or separately (NHFE6 and NHFE7 cells)
immediately alter checkpoint control. Whereas normal cells
will respond to a negative growth signal (confluence, DNA
damage, or metabolic inhibitors) by an arrest in cell cycle
progression, E6/E7- or T-antigen-expressing cells fail to do so
(50, 61). In all cases, these cells can proliferate in culture for a
limited amount of time and then senesce. These oncoprotein-
expressing cells have clearly lost control of genomic integrity
prior to immortalization. To understand the molecular basis of
checkpoint control and how it is lost in these cells, we analyzed
cyclin complex perturbations in NHFs expressing viral onco-
proteins.
It is now well established that the primary control of the
eukaryotic cell division cycle is provided by a family of serine/
threonine protein kinase complexes consisting of a catalytic
subunit (cyclin-dependent kinase [CDK]) and a regulatory sub-
unit (cyclin) (8, 43). Cyclins were originally discovered in in-
vertebrate eggs as proteins whose abundance after fertilization
oscillated during early cleavage divisions as a result of their
active synthesis and abrupt proteolytic degradation at mitosis
(13). Subsequently, cyclin genes have been isolated from vir-
tually all eukaryotic species and found to constitute a multi-
gene family (reviewed by Xiong and Beach [62]). In unicellular
yeast cells, a single prototype CDK gene, cdc2 of the fission
yeast Schizosaccharomyces pombe or CDC28 in the budding
yeast Saccharomyces cerevisiae, in conjunction with the various
types of cyclins controls both the G1/S (Start) and G2/M (mi-
tosis) transitions. In humans and other higher eukaryotes, how-
ever, CDKs also constitute a multigene family. At least six
CDK genes, CDC2 (or CDK1) and CDK2, -3, -4, -5, and -6,
have been identified in human cells. Each CDK can apparently
interact with any one of the multiple cyclin regulatory subunits,
although sometimes favoring a particular one (reviewed by
Sherr [55] and Pines [49]). In NHFs, cyclin-CDK pairs further
associate with two additional proteins, proliferating cell nu-
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clear antigen (PCNA) and p21, to form a potentially large
number of quaternary complexes (64, 65, 67). Upon transfor-
mation of diploid fibroblasts with the DNA tumor virus SV40
or its transforming tumor antigen, the cyclin-CDK-p21-PCNA
complexes undergo drastic subunit rearrangement including
dissociation of both p21 and PCNA from cyclin-CDK com-
plexes (65). The pattern of subunit rearrangement of cyclin-
CDK complexes in SV40-transformed cells is also shared in
those containing adenovirus or papillomavirus oncoproteins.
To specifically address which viral oncoprotein alters the
cyclin-CDK complexes and when such alterations occur, before
or after the cell transformation, we analyzed in detail the
subunit compositions of the complexes in mortal, nontrans-
formed cells expressing individual viral oncoproteins that spe-
cifically inactivate either p53 or the Rb family of proteins. The
biologic consequences of the expression of these viral oncop-
roteins that lead to alterations of cyclin-CDK complexes in-
clude defects in cell cycle checkpoint control and are seen as
the accumulation of cytogenetic abnormalities as these cells
propagate. These changes occur prior to cell transformation.
MATERIALS AND METHODS
Cell populations and culture conditions.All cells were grown in alpha minimal
essential medium without nucleosides and deoxyribonucleosides but containing
glutamine and 10% dialyzed fetal bovine serum (JRH Biosciences). Primary
human foreskin fibroblasts were obtained from M. Cordiero-Stone, University of
North Carolina at Chapel Hill. At passage 10 or 11, cells in log-phase growth
were infected with retroviral vectors containing only the neomycin resistance
gene (vector LXSN) or a vector containing the neomycin gene and HPV16 open
reading frames for the E6 and/or E7 proteins (LXSN16E6E7, LXSN16E6, or
LXSN16E7). The vectors were a gift from Denise Galloway, Fred Hutchison
Cancer Center, Seattle, Wash. Retroviral infection, population doubling time
determination, and karyotypic analysis were performed as described previously
(61).
Karyotypic analysis. The procedure used to obtain G-banded chromosomes
was previously described (34). Fifty metaphase spreads from each cell population
were analyzed, and results are expressed as a percentage of cells exhibiting the
indicated karyotype.
Immunoprecipitation of viral and cellular proteins. Cells (2 3 106) were
incubated in methionine- and cysteine-free Dulbecco modified Eagle medium for
1 h at 378C and were then labeled for 3 h with 80 mCi of Tran35S-Label (70%
L-[35S]methionine and 15% L-[35S]cysteine; ICN) per ml. Incubation in 800 ml of
lysis buffer (20 mM Tris [pH 7.4], 250 mM NaCl, 0.5% Nonidet P-40, 1 mM
EDTA, 50 mg of leupeptin per ml, 30 mg of aprotinin per ml) for 10 min at 48C
was followed by centrifugation at 14,000 rpm for 30 min to remove cellular
debris. Lysates were precleared by absorption with Sansorbin (Calbiochem) for
30 min on ice and microcentrifuged 15 min. Equivalent trichloroacetic acid-
precipitable counts (5 3 107) of radioactive protein were immunoprecipitated
with protein A-Sepharose coated with mouse anti-HPV18/16 E6 (Oncogene
Science), anti-HPV16 E7 (Denise Galloway), anti-human p53 protein (p53 Ab-5;
Oncogene Science), or anti-Rb antibody (RB Ab-1; Oncogene Science) for 2 h.
Immune complexes were washed four times in wash buffer (20 mM Tris [pH 7.4],
150 mM NaCl, 0.5% Nonidet P-40, 0.1% sodium dodecyl sulfate [SDS]) and
twice in phosphate-buffered saline, released from the beads by heating to 958C,
and separated by electrophoresis on SDS–12% polyacrylamide gels (PAGE).
Gels were fixed, treated with Amplify (Amersham), dried, and exposed to X-ray
film.
Immunochemistry procedures. [35S]methionine metabolic labeling and West-
ern blotting procedures (immunoblotting) were as previously described (65).
Anti-E7 antibodies were a gift of John Schiller (National Institutes of Health,
Bethesda, Md.) and have been previously characterized by Androphy et al. (1)
and Firzlaff et al. (16).
RESULTS
Expression of the HPV16 oncoproteins in NHFs. NHF1 cells
were infected with amphotropic retroviral vectors carrying the
neomycin resistance gene alone (NHF/neo cells) or in combi-
nation with HPV16-encoded oncoprotein E6 or E7 as de-
scribed previously (61). Expression of both viral proteins in
NHFs was examined by [35S]methionine metabolic labeling as
shown in Fig. 1. 35S-labeled lysates were prepared and immu-
noprecipitated with an antibody specific to either HPV E6 or
HPV E7 (1, 16). An 18-kDa protein corresponding to the
expected size of HPV E6 was specifically precipitated by the
anti-E6 antibody from NHFs infected with a recombinant ret-
rovirus containing the HPV E6 gene (lane 3) or both E6 and
E7 genes (lane 7). A 19-kDa protein corresponding to the
expected size of E7 protein was evident in anti-E7 immuno-
precipitations derived from NHFs cells infected with a retro-
virus carrying the HPV E7 gene alone (lane 6) or carrying both
HPV E6 and E7 genes (lane 8). Consistent with its role in
facilitating the degradation of p53 (52, 60), a severe reduction
in p53 protein levels was observed in cells expressing E6 (data
not shown). It should be noted that these studies are done with
populations of fibroblasts which express significant amounts of
E6 and E7 proteins. Normally, HPV infects epithelial cells, and
these genes are most likely expressed at a lower level.
Characterization of chromosome complements in HPV-in-
fected NHFs. The oncoprotein-expressing cells were previously
shown to generate drug-resistant colonies, indicating that they
had the potential to be genomically unstable when challenged
with a negative growth signal (61). To further elucidate the
molecular basis by which the variants arise, we examined the
chromosomal condition of these cells while they were grown in
culture. Karyotypic stability was examined in uninfected and
HPV-infected NHFs, with samples taken soon after the viral
oncogene-expressing populations were selected as well as prior
to their senescence in culture (Table 1). Normal cells senesce
after ;72 population doublings (PDL) in culture, while the
E6/E7-expressing populations have an extended life span of
;20 PDL. Cells expressing each oncoprotein individually se-
nesce around PDL 82. Normal, diploid karyotypes were ob-
served in the parental NHFs both at early passage and at a
PDL close to senescence. Infrequently, there is a random loss
of a single chromosome or the observation of a tetraploid cell.
These observations are in keeping with those reported in the
literature (2). At early passage after infection with the indi-
cated oncoprotein-coding genes, the NHF/neo, NHFE6, and
NHFE7 cells displayed karyotypes that were indistinguishable
from those of the parental NHFs (Table 1) (61). All four
populations have a basic normal karyotype, with no rearrange-
ments detected. Aneuploidy is found in less than 10% of the
cells. The karyotypes of the NHFE6/E7 cells at early passage
are similar to those of the parental NHFs in that less than 10%
of the cells are aneuploid, yet these cells were found to have
telomeric association (defined as end-to-end fusion of chromo-
FIG. 1. Expression of HPV16 E6 and E7 genes in NHFs. [35S]methionine-
labeled cell lysates were prepared as described previously (65) from the indicated
cell lines. Cell lysates were immunoprecipitated with an antibody specific to E6
(lanes 1, 3, 5, and 7) or E7 (lanes 2, 4, 6, and 8). The positions of E6 and E7
proteins are marked on the left, and molecular weight markers are indicated at
the right.
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somes) in 8% of the cells and rearrangements in 6% of the
cells. The telomeric association figures seen were simple, each
consisting of two recognizable chromosomes attached at their
telomeres, with no noticeable loss or gain of chromatin at the
junctions.
At late passage, the different effects of E6 and E7 are re-
vealed. The E7-expressing cell population retained a normal,
diploid karyotype, even at two PDL from senescence (Table 1).
In contrast, upon passage in tissue culture (with no overt in-
troduction of damage), the E6/E7- and E6-expressing cells
have similar, highly aberrant karyotypes. The NHFE6/E7 and
NHFE6 cell populations lost any semblance of a diploid chro-
mosome karyotype; mean chromosome count for the
NHFE6/E7 cells was 68 (range, 37 to .100), while the mean
chromosome count for the NHFE6 cells was 69 (range, 40 to
.100); these means are underestimates since cells with more
than 100 chromosomes were tallied as having exactly 100 chro-
mosomes. Virtually all of the cells (.95%) in these two pop-
ulations have complex chromosome rearrangements and telo-
meric associations. Often the chromosomes involved could not
be recognized. Some telomeric association figures consisted of
strings of several chromosomes attached end to end, and some
had extra or missing material at their junctions. Some of the
dicentrics figures observed were the result of a single chromo-
some duplicating one of its own arms and centromere region
rather than the result of telomeric association.
To verify that the increased aneuploidy and rearrangements
observed in the later-passage E6/E7-expressing cells was not
simply a reflection of their increased number of PDL (because
of extended life span), we also examined their karyotypes at an
intermediate PDL that corresponded to the samplings of the
E6- or E7-expressing populations prior to senescence. As
noted in Table 1, increased rearrangement and telomeric as-
sociation were also observed in the NHFE6/E7 cells at that
point in time as well. At earlier passage, usually the telomeric
association and rearrangements were simple, involving only
two chromosomes at a time, and were not totally random. In
the NHFE6/E7 cell population at intermediate passage, chro-
mosomes 12p and X were often involved. The types of chro-
mosomal abnormalities that were observed as the NHFE6/E7
cell population progressed in culture followed a discernible
order (see Discussion).
Cyclin-CDK complexes in the parental cells. Our previous
studies have shown that NHFs have checkpoint responses that
are intact and will arrest in the G1 and G2 phases of the cell
cycle when exposed to a negative growth signal or DNA dam-
age (references 34 and 61 and unpublished observations). It is
hypothesized that these pauses in cell cycle progression pre-
vent the use of damaged DNA for replication and its segrega-
tion, preventing the formation of chromosomal abnormalities.
Deviations from this pattern are seen in NHFs expressing
HPV16 viral oncoproteins (61). These cells fail to arrest when
challenged with a negative growth signal. To implicate the
cyclin involvement in these alterations in cell cycle control, we
examined the complexes of cyclins D1, A, and B1 in the on-
coprotein-expressing cells. Since rearrangement of quaternary
complexes has been found to be extensive in fully transformed
cells, we sought to examine these complexes in their nontrans-
formed progenitors. To ensure that any changes were regula-
tory in nature, rather than a product of genomic alteration,
only cyclin complexes from early-passage cells (passages 42 to
48), which exhibited a normal karyotype, were examined.
First, we characterized the cyclin-CDK complexes in NHFs
and NHF/neo cells for comparison with previous normal cell
populations (Fig. 2). [35S]methionine-labeled cell lysates de-
rived from NHFs and NHF/neo cells were immunoprecipitated
with a battery of six antibodies (anti-human CDC2, CDK2,
CDK4, cyclin A, cyclin B1, and cyclin D1). In both cell popu-
lations, association of p21 with each of the cyclin and CDK
complexes was readily observable, as in other NHF cell lines
previously characterized (63, 67). However, the intensity of the
PCNA protein band in cyclin-CDK complexes, as determined
by the metabolic labeling, is much lower than that observed in
other NHF lines. To address this issue, we performed immu-
noblotting coupled with immunoprecipitation (Fig. 3). PCNA
proteins were readily detected by Western blotting in all cyclin
and CDK complexes of normal cells with the exception of
CDC2 complexes, which contained a barely detectable level.
We have observed somewhat similar phenomena before and
do not yet fully understand this apparent experimental discrep-
ancy between metabolic labeling andWestern blotting between
the different NHF populations. For example, the levels of
PCNA protein present in both cyclin D1 and CDK4 complexes
are similar in NHFs, NHF/neo cells, and NHFE7 cells, as
determined by Western blotting (compare lanes 4, 5, and 7 in
Fig. 3), but the intensity of the [35S]methionine-labeled PCNA
band is much higher in NHFE7 cells (see Fig. 5) than in NHFs
or NHF/neo cells. A possible explanation for this is that the
rate of PCNA synthesis and its recruitment into cyclin-CDK
complexes differ in different types of cells.
Cyclin-CDK complexes in NHFE6 cells. As shown below,
expression of HPV16 E6 dramatically decreases the level of
p21 mRNA (see Fig. 8). We examined the association of p21
protein with the cyclin complexes in these cells. Interestingly,
the amount of p21 protein present in the cyclin D1- and cyclin
A-CDK complexes (as determined by metabolic labeling) is
similar to that seen in NHFs and NHF/neo cells (Fig. 4).
However, no p21 protein was detected in [35S]methionine-
labeled anti-CDC2 and anti-cyclin B1 immunoprecipitates
(Fig. 4, lanes 1 and 7). CDC2 and cyclin B1 are the major
catalytic (CDC2) and regulatory (cyclin B1) partners of each
other. Together, these results suggest that p21 has different


















NHF 100 0 0 0 0
NHF/neo (PDL
40)
94 6 0 0 0
NHF16 E6/E7
(PDL 46)
96 0 4 8 6
NHFE6 (PDL 56) 100 0 0 0 0
NHFE7 (PDL 50) 96 4 0 0 0
Late passage
NHF (PDL 70) 94 0 6 0 0
NHFE6/E7
PDL 56 94 2 4 14 2
PDL 73 90 4 6 48 56
PDL 98 20 4 76 100 100
NHFE6
PDL 69 94 2 4 44 66
PDL 88 20 0 80 96 98
NHFE7 (PDL 76) 100 0 0 4 0
a Karyotypic analysis of oncoprotein-expressing cells was compared with that
of parental cells at various times during passage in culture. The data for early-
passage cells are from White et al. (61).
b End-to-end joining of chromosomes.
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association affinities for different cyclin-CDK complexes and
that the reduced level of p21 may selectively dissociate p21
from specific cyclin-CDK complexes.
PCNA protein was not seen in any [35S]methionine-labeled
cyclin or CDK immunoprecipitates derived from NHFE6 cells
(Fig. 4). The profound dissociation of PCNA from cyclin-CDK
complexes was further confirmed by immunoblotting (Fig. 3).
The level of total PCNA protein in NHFE6 cells is similar to
that in NHFs or NHF/neo cells (compare lane 6 with lanes 4
and 5), as determined by immunoblotting of the total cell
lysate, yet this protein is not found in complexed form. The
dissociation of PCNA protein from cyclin-CDK complexes is
specific to the oncogenic forms of HPV, since a normal level of
PCNA protein was detected in NHFs expressing the nononco-
genic form of E6 from HPV6, and the PCNA is found in
association with the cyclin complexes, albeit to a slightly di-
minished degree (Fig. 3). The major biological function known
to associate with the oncogenic E6 from high-risk HPV16 but
not low-risk HPV6 is binding to and promoting the in vitro
degradation of p53 (52, 60). Thus, this finding suggests that in
addition to regulating the transcription of p21 (see below), p53
may also indirectly regulate the association of PCNA with
cyclin-CDK complexes.
Cyclin-CDK complexes in NHFE7 cells. We next investi-
gated the cyclin-CDK complexes in NHFE7 cells. Unlike the
cells expressing HPV16 E6, quaternary complexes are very
much intact in cells expressing the E7 oncoprotein. Indeed, the
intensities of both p21 and PCNA as determined by [35S]me-
thionine-labeling are considerably higher than those seen in
NHFs and NHF/neo cells (Fig. 5). The higher levels of PCNA
in all cyclin-CDK complexes as detected by [35S]methionine
labeling were further confirmed by immunoblotting experi-
ments (Fig. 3). While the total amount of PCNA protein in
NHFE7 cells (Fig. 3, lane 7) is similar to that in NHFs or
NHF/neo cells (lanes 4 and 5) and slightly higher than that in
NHFE6 cells (lane 6), PCNA protein is present in all cyclin and
CDK complexes at levels either similar to (cyclin D1 and
CDK4) or considerably higher than (cyclin B1, cyclin A,
CDC2, and CDK2) levels in NHFs and NHF/neo cells. The
increased association of PCNA with these cyclin-kinase com-
plexes is specific to E7 of HPV16 since the low-risk form does
not show a significant change in the PCNA binding (lane 2).
Increased association of both p21 and PCNA with cyclin-CDK
complexes in cells expressing E7 proteins points to the possi-
bility that in addition to being regulated by p53, the cell cycle
machinery is regulated by a pathway involving the Rb family of
proteins (Rb, p107, p130, etc.). These changes have previously
been associated with altered checkpoint control (61).
Cyclin-CDK complexes in NHFE6/E7 cells. The different
effects of E6 and E7 on the genomic stability and cyclin-CDK
complexes prompted us to further analyze the cyclin-CDK
complexes in NHFE6/E7 cells. As in cells expressing E6 alone,
no PCNA was detected, either by [35S]methionine labeling
(Fig. 6) or by immunoblotting (Fig. 3, lane 8), in any cyclin-
CDK immunocomplexes derived from NHFE6/E7 cells (ex-
cept perhaps a trace amount of PCNA in CDK2 immunopre-
cipitates). However, expression of E6 together with E7 had
apparently different effects on the association of p21 with cy-
clin-CDK complexes than expression of either E6 or E7 alone.
p21 protein is totally absent from all cyclin-CDK complexes, as
determined by [35S]methionine labeling. Therefore, it appears
that while the expression of E6 alone is sufficient to dissociate
PCNA from cyclin-CDK complexes, expression of both E6 and
E7 is required for the complete absence of p21 from cyclin-
CDK complexes. The configuration of cyclin-CDK complexes
in NHFE6/E7 cells is very much the same as that in cells fully
transformed by SV40 (VA13 or CT10 cells), adenoviruses (293
cells), or papillomaviruses (HeLa cells [65]). The one excep-
FIG. 2. Cyclin-CDK complexes in NHFs and NHF/neo cells. [35S]methionine-labeled cell lysates were prepared from NHFs (strain NHF1) or NHF/neo cells and
immunoprecipitated with one of six antisera, each specific to a cyclin or CDK, with or without prior incubation with a competing antigen peptide (pep) (as indicated
above each lane) and resolved by SDS-PAGE. The relative positions of the molecular weight markers and proteins whose identities have been established are marked.
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tion is cyclin A-CDK2. In fully transformed cells, this complex
associates with the p19 protein, but in E6/E7-expressing cells,
it is not detected. These results indicate that the subunit rear-
rangement of cyclin-CDK complexes previously observed in
fully transformed cells occurred before rather than after neo-
plastic transformation, suggesting that such alterations of cell
cycle machinery may be a prerequisite for, not a consequence
of, cellular transformation.
Cyclin D-CDK4 complexes. Unlike cyclin B1-CDC2 and cy-
clin A-CDK2 complexes, whose binary association is not af-
fected in fully transformed cells, cyclin D-CDK4 association is
totally disrupted in transformed cells in addition to the disso-
ciation of p21 and PCNA (65). This phenomenon was further
investigated by immunoblotting lysates from NHFs expressing
individual HPV oncoproteins. Anti-cyclin D1 and anti-CDK4
immunoprecipitates derived from the panel of cells were
probed by both anti-cyclin D1 and anti-CDK4 antibodies si-
multaneously to examine their levels and to determine the
association between them (Fig. 7). It is evident from this ex-
periment that the expression of HPV16 E6 alone not only
dissociates p21 and PCNA from cyclin D1 and CDK4 com-
plexes but also drastically disrupts the binary association of
cyclin D1-CDK4. Only a very small fraction of the cyclin D1
and CDK4 is found associated with each other in cells express-
ing E6. The slight discrepancy between immunoblotting (Fig.
7) and metabolic labeling (Fig. 4, lane 4) may reflect more
sensitive detection by the latter assay because of the very short
half-life of cyclin D1 (;30 min [54]). Expression of E7 has little
effect on the cyclin D1-CDK4 complex, but when E7 is ex-
pressed together with E6, it appears that the disruption was
more complete (Fig. 7, lanes 5 and 12; Fig. 6, lanes 4 and 7).
The effect of E6 on cyclin D1-CDK4 complexes is specific to
the oncogenic forms of HPV, since expression of nononco-
genic HPV6 E6 did not show any effect on their association.
Together with the observations that expression of HPV16 E6
down regulates the level of p21 mRNA and also disrupts the
PCNA association with cyclin-CDK complexes, it is possible
that the cyclin D-CDK4 complexes are stabilized by p21 and
PCNA association. Experiments with cyclin D1 and CDK2
yielded similar results (data not shown).
p16-CDK4 complexes. In SV40-, adenovirus-, and papillo-
mavirus-transformed cells, CDK4 proteins dissociate from cy-
clin D1 and exclusively associate with p16 (65). This observa-
tion is in agreement with the report of absence of cyclin D
protein and cyclin D-CDK complexes in cells lacking pRb (4,
33, 46, 51). Consistent with previous reports, expression of
either E6 or E7 alone promotes the formation of p16-CDK4
complexes at least 10-fold above that seen in parental cells
(compare lanes 4 and 5 of Fig. 4 and 5 with lanes 5 and 6 of Fig.
2A and B). In cells expressing both E6 and E7, all CDK4 is
associated with p16, and the level of this binary complex was
significantly higher than with either oncoprotein alone, further
reinforcing the notion that both p53 and Rb may negatively
regulate the expression of p16 (33). Increased levels of p16 in
fully transformed or E7-expressing cells result in part from the
release of transcriptional repression of the p16 gene by Rb
(33).
Expression of p21 mRNA in HPV-infected NHFs. Using the
recently isolated human p21 cDNA probe (63), we investigated
the steady-state levels of p21 mRNA in NHFs as well as in
NHFs expressing HPV oncoproteins (Fig. 8). Total RNAs pre-
pared from the panel of cells were subjected to Northern
(RNA) analysis and hybridized with a full-length p21 cDNA
probe. Strikingly, expression of E6 dramatically reduced the
FIG. 3. Immunoblotting analysis of PCNA association with cyclin-CDK com-
plexes. Total cell lysates were prepared from two NHF cell lines (IMR-90 and
NHF1; lanes 3 and 4) and NHF-1 cells transfected with retroviral vectors con-
taining the neomycin resistance gene (neo; lane 5), low-risk HPV6 E6 oncogene
(lane 1), HPV6 E7 oncogene (lane 2), high-risk HPV16 E6 oncogene (lane 6),
HPV16 E7 oncogene (lane 7), and HPV16 E6 together with HPV16 E7 (lane 8).
These cell lysates were immunoprecipitated with one of six antisera, each specific
to a cyclin or CDK (as indicated above each set of lanes), and resolved by
SDS-PAGE. In the panel at the top, total lysates from each cell line were
resolved by SDS-PAGE without immunoprecipitation. Proteins resolved on an
SDS-polyacrylamide gel were electrotransferred to a nitrocellulose filter, and the
blots were probed with a monoclonal antibody specific to PCNA.
FIG. 4. Subunit rearrangement of cyclin-CDK complexes in NHFE6 cells.
[35S]methionine-labeled cell lysates were prepared from NHFE6 cells. Labeled
cell lysates were immunoprecipitated with six antisera, each specific to a cyclin or
CDK, with or without prior incubation with a competing antigen peptide (pep)
(as indicated above each lane) and resolved by SDS-PAGE. The relative posi-
tions of the molecular weight markers and proteins whose identities have been
established are marked.
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level of p21 mRNA (Fig. 8, lane 3). This effect is specific to the
oncogenic form of HPV16 E6 since expression of nononco-
genic HPV6 E6 had little effect on the level of p21 mRNA
(lane 6), indicating that p53 may directly regulate the transcrip-
tion of p21. These results are entirely consistent with a report
that p21 encodes a major transcript whose transcription is
induced by wild-type but not mutant p53 (11). Expression of
E7 has little effect on the level of p21 mRNA. Similarly, low
levels of p21 mRNA are seen in cells expressing E6 alone or E6
plus E7, yet p21 protein is associated with cyclin-CDK com-
plexes (D1 and A) in E6-expressing cells but not E6/E7-ex-
pressing cells; this result suggests that E7 activity can also affect
the association of p21 with cyclin-CDK complexes. Cellular
proteins such as Rb, p107, and p130 may be involved in the
posttranscriptional modification or localization of p21.
DISCUSSION
The origin and development of human tumors begin at the
molecular level and involve a complex multistep process. Cor-
related with this process is the loss of genomic integrity, a
hallmark of neoplastic cells (15, 18, 26, 44). The dependence of
cell cycle progression on genomic integrity has been described
as checkpoint control (24). Many recent efforts in the study of
genomic integrity have focused on elucidating the molecular
pathway(s) of checkpoint control in normal cells and how such
a pathway(s) is altered or becomes defective during cellular
transformation. In human fibroblasts fully transformed by a
variety of viral oncoproteins, including E6 and E7, the primary
regulators of eukaryotic cell cycle, CDKs, are grossly altered
(65). We have demonstrated that in preneoplastic mortal cells,
checkpoint control is disrupted by divergent pathways by ex-
pression of either the E6 or E7 viral oncoprotein of HPV (61)
or T antigen of SV40 (50). We have now further analyzed the
subunit composition of CDKs in preneoplastic mortal cells
expressing HPV E6 and E7 in an attempt to resolve how the
viral oncoproteins alter cell cycle machinery and observe the
effects on genomic integrity.
Alteration of cyclin-CDK complexes in preneoplastic cells.
In NHFs, CDKs predominantly exist as quaternary complexes,
each consisting of a cyclin, a CDK, PCNA, and p21. Upon
cellular transformation by DNA tumor viruses, the cyclin-
CDK-p21-PCNA complexes undergo a dramatic subunit rear-
rangement (65), indicating that a common mechanism may be
used by these different tumor viruses in altering normal cell
cycle control. However, since those experiments were carried
out in fully transformed cells, it is not possible to tell when the
alteration occurred, before or after the cell transformation.
Using NHFs expressing viral oncoproteins E6 and E7 (61), we
demonstrate here that cyclin-CDK complexes are grossly al-
tered in preneoplastic mortal cells (Fig. 9). Analyses per-
formed in early- and mid-passage cells yielded identical results.
The subunit composition of all cyclin-CDK complexes that we
have examined is the same in NHFE6/E7 cells as that observed
in fibroblast cells fully transformed by SV40, adenoviruses, or
papillomaviruses (Fig. 6 and reference 65). Specifically, no p21
or PCNA is associated with the various cyclin-CDK complexes,
and CDK4 becomes exclusively associated with the kinase in-
hibitor p16 (53), with concomitant disruption of cyclin D1-
CDK4 binary association. Hence, the subunit rearrangement
of cyclin-CDK complexes is a direct effect of viral oncoprotein
expression rather than a consequence of cellular transforma-
tion. We suggest from these observations that alteration of
cyclin-CDK complexes is a major target of viral oncoprotein
function and a prerequisite for cellular transformation.
FIG. 5. Subunit rearrangement of cyclin-CDK complexes in NHFE7 cells.
[35S]methionine-labeled cell lysates were prepared from NHFE7 cells. Labeled
cell lysates were immunoprecipitated with six antisera, each specific to a cyclin or
CDK, with or without prior incubation with a competing antigen peptide (pep)
(as indicated above each lane) and resolved by SDS-PAGE. The relative posi-
tions of the molecular weight markers and proteins whose identities have been
established are marked.
FIG. 6. Subunit rearrangement of cyclin-CDK complexes in NHFE6/E7 cells.
[35S]methionine-labeled cell lysates were prepared from NHFE6/E7 cells. La-
beled cell lysates were immunoprecipitated with six antisera, each specific to a
cyclin or CDK, with or without prior incubation with a competing antigen
peptide (pep) (as indicated above each lane) and resolved by SDS-PAGE. The
relative positions of the molecular weight markers and proteins whose identities
have been established are marked.
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Alteration of cyclin-CDK complexes and loss of genomic
integrity. Although ubiquitous, the presence of HPV16 or
HPV18 is not sufficient to trigger malignant progression. The
virus may be present with a long latency, and only rarely does
progression of genital lesions into carcinomas occur (68). The
so-called high-risk HPVs are carried in an episomal state in
benign tumors and are found in an integrated state in malig-
nant lesions (9, 47). This integration event is accompanied by
a change in transcription activity and pattern (3, 32). In the
episomal state, an entire spectrum of viral proteins used for
replication, capsid formation, etc., is expressed, whereas in the
integrated state, the E6 and E7 viral oncogenic products be-
come the dominant transcripts (9, 47). Our studies have doc-
umented the effect of the expression of these oncoproteins on
checkpoint control and genomic stability (61).
Genetic instability in the HPV oncoprotein-expressing cells
is evident in the absence (Table 1) as well as in the presence
(61) of N-phosphonoacetyl-L-aspartate selection. Yet, while
expression of each oncoprotein individually allows the gener-
ation of drug resistance (i.e., genomic instability), the types of
changes that occur differ dramatically. Cells that contain com-
promised p53 function (cells expressing E6 alone or E6 and
E7) survive, with chromosomes that have evidently been bro-
ken and rejoined. Translocations, amplifications, and deletions
are evident (Table 1 and reference 61). These rearrangements
increase dramatically as the cells are passaged beyond the
threshold of senescence. In contrast, in cells that retain p53
function but are altered in the Rb family of proteins (cells that
are expressing E7), the breakage abnormalities are not ob-
served. One possibility for this phenomenon is that physical
damage to the genome, such as DNA breaks postulated in the
bridge-breakage-fusion cycles (favored as a mechanism by
which gene amplification occurs), trigger p53 activation, and
these cells are cleared from the population. Under adverse
conditions (i.e., lack of metabolites or the presence of DNA
breaks), these cells commit suicide rather than deal with un-
favorable consequences. Whole chromosome anomalies, aris-
ing from nondisjunction, may not trigger p53 activity and are
thereby permitted. Either the breaks do not occur in the first
place or the cells that contain them selectively die. Either of
these processes would result in the relatively normal karyotype
seen in the late-passage E7-expressing cells. Only whole chro-
mosome changes (such as polyploidy or aneuploidy) are com-
patible with viability in these cells. As demonstrated previously
(61), the sole mechanism of drug resistance in the E7-express-
ing cells is an increase in the whole chromosome 2. It should be
FIG. 7. Immunoblotting analysis of cyclin D1-CDK4 complexes. Total cell
lysates were prepared from NHF1 cells (lanes 1 and 8) and NHF-1 cells trans-
fected with retroviral vectors containing the neomycin resistance gene (neo;
lanes 2 and 9), high-risk HPV16 E6 oncogene (lanes 3 and 10), HPV16 E7
oncogene (lanes 4 and 11), and HPV16 E6 and E7 oncogenes (lanes 5 and 12),
low-risk HPV6 E6 oncogene (lanes 6 and 13), and low-risk HPV6 E7 oncogene
(lanes 7 and 14). Lysates were immunoprecipitated with either an anti-cyclin D1
(lanes 1 to 7) or anti-CDK4 (lanes 8 to 14) antiserum. Immunoprecipitates
resolved on an SDS-polyacrylamide gel were electrotransferred to a nitrocellu-
lose filter, and the membranes were probed with a mixture of antisera against
cyclin D1 and CDK4.
FIG. 8. Expression of p21 mRNA in fibroblasts expressing viral oncopro-
teins. Total RNA was prepared from NHFs (lane 1) and NHFs infected with
amphotropic retroviruses carrying a neomycin resistance marker (neo; lane 2),
genes encoding high-risk HPV16 E6 (lane 3), E7 (lane 4), and E6 plus E7 (lane
5), and genes encoding low-risk HPV6 E6 (lane 6) and E7 (lane 7). RNA samples
were resolved on a 1% agarose gel (lower panel) and transferred to a nitrocel-
lulose filter. The membrane was hybridized with a probe derived from the p21
cDNA (top panel). The positions of p21 mRNA and 18S and 28S rRNAs are
indicated at the left.
FIG. 9. Summary of proteins associated with cyclins and CDKs. Primary
associations are depicted in cartoon fashion. Arrows located beside complexes
indicate a change in the quantity of the complex detected by the methods
described in the text. Data for the fully transformed cells were taken from Xiong
et al. (65).
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noted that aneuploidy is the most frequent genomic change
found in transformed cells.
Effects of E6 on cyclin-CDK complexes. Using NHFs ex-
pressing only the E6 or E7 oncoprotein, we were able to ad-
dress how the individual oncogenic activity of each affects and
activates the cell cycle machinery. Expression of high-risk
HPV16 E6, but not low-risk HPV6 E6, dramatically decreases
the level of p21 mRNA (Fig. 8). Significant reduction of p21
mRNA was also observed recently in a different line of NHF
expressing HPV16 E6 (33). As only HPV16 E6 binds to and
targets the degradation of p53 (6, 28, 52), these results provide
further support for the current model that p21 is transcription-
ally regulated (at least in part) by p53 (11). p21 has recently
been shown to encode a potent inhibitor of CDKs (20, 22, 63).
Thus, stimulation of reentry into the cell cycle by DNA tumor
viruses can be partially explained by the decrease in the level of
p21’s inhibitory function.
Expression of E6 alone did not completely abolish the ex-
pression of p21, presumably because of incomplete degrada-
tion and inactivation of p53. p21 protein was still present in
many of the cyclin-CDK complexes. However, the limited
amount of p21 is likely to associate with cyclins and CDKs at a
reduced level, as evidenced by the selective dissociation of p21
from the cyclin-CDK complexes to which p21 has the lowest
affinity, such as CDC2 and cyclin B1 (Fig. 4). In addition to the
reduced level and association of p21 with cyclin-CDK com-
plexes, PCNA was not present in any of cyclin-CDK complexes
(Fig. 4). Since we never observed association of PCNA with
cyclin and CDK without p21, these findings suggest that the
association of PCNA with cyclin-CDK complexes may be
bridged by p21. This is consistent with the existence of two
functionally distinct domains of the p21 molecule, a CDK-
inhibitory domain located in the amino-terminal half and a
PCNA-binding domain in the carboxyl-terminal half (5, 36, 42,
58). Taken together, the data suggest that expression of onco-
genic E6 not only impairs the p53 activation of p21 expression
but also completely abolishes the as yet unidentified function
of PCNA in regulating the activity of CDKs. Such drastic
alteration in the regulation of cell cycle kinases correlates with
the karyotypic analysis that shows loss of genetic stability in
E6-expressing cells (Table 1; see above).
Effects of E7 on cyclin-CDK complexes. Conversely, expres-
sion of E7 alone neither affected the expression of p21 nor
altered the subunit composition of cyclin-CDK quaternary
complexes. Unexpectedly, E7 appears to somehow increase the
association of p21 and PCNA with cyclin-CDK complexes. A
considerably higher amount of PCNA was detected in cyclin
B1-CDC2 and cyclin A-CDK2 complexes in E7-expressing
cells than in normal cells (Fig. 3). This effect is specific to the
oncogenic form of E7, since the expression of low-risk E7 of
HPV6 did not show the same effect (Fig. 3). As the levels of
p21 and PCNA protein measured in E7-expressing cells are
similar to those in normal cells, we do not yet know the mech-
anism by which E7 expression increases the association of p21
and PCNA with cyclin-CDK complexes. One possibility is that
expression of E7 can directly or indirectly posttranslationally
modify p21. Recent reports have demonstrated an indepen-
dent association between p21 and PCNA (17, 57). The reports
demonstrate that direct binding of p21 to PCNA inhibits DNA
replicative synthesis. Our results show that in cells with a func-
tionally inactivated p53, PCNA is no longer associated with the
cyclin quaternary complex (Fig. 3, 4, 6, and 9). This finding
suggests that p21 is not the sole determinant of PCNA associ-
ation in cyclin-CDK complexes. The finding that quaternary
cyclin-CDK complexes are elevated but remain intact in E7-
expressing cells suggests that different aspects of genomic in-
tegrity are monitored by different cellular components. The
alteration provoked by the expression of E7 in normal cells is
compatible with the generation of aneuploidy but not amplifi-
cation (reference 61 and Table 1; also see discussion above).
Interestingly, coexpression of E6 and E7 leads to further
alteration of CDKs. p21 is completely absent from all cyclin-
CDK complexes, in addition to the complete dissociation of
PCNA (Fig. 6). Since expression of E7 alone did not affect the
level of p21 message, this finding reinforces the suggestion that
E7 activity may posttranscriptionally regulate p21. This finding
further suggests that the requirement of both oncogenic activ-
ities for cellular transformation may be due to a requirement
for both activities in order to completely dissociate p21 and
PCNA from cyclin-CDK complexes.
No effects with low-risk viral oncoproteins. It should be
noted that all alterations of cyclin-CDK complexes described
here are specific to the oncogenic form of viral proteins that
were derived from high-risk types of HPV. Expression of nei-
ther E6 nor E7 derived from low-risk HPV has any effect on
the expression of individual components or formation of cy-
clin-CDK-p21-PCNA complexes. This is particularly evident in
the case of p21 mRNA expression, in which case HPV16 E6
dramatically reduced the level of p21 mRNA whereas expres-
sion of HPV6 E6 had no effect (Fig. 8). Increased association
of PCNA with cyclin-CDK complexes was also seen in cells
expressing HPV16 E7 but not in cells expressing HPV6 E7
(Fig. 3). Studies of human cell transformation have shown that
HPV6 does not immortalize primary human epithelial cells
(21, 48). There is no evidence reported of complex formation
between HPV6 E6 and cellular p53, and the affinity of HPV6
E7 protein for cellular Rb is approximately 10-fold lower than
the affinity of HPV 16E7 for Rb (19, 40). In the presence of
N-phosphonoacetyl-L-aspartate, the NHFs separately express-
ing the E6 and E7 proteins of the low-risk HPV exhibited a
phenotype typical of uninfected NHFs; they retain cell cycle
checkpoint control and fail to produce drug-resistant colonies.
These observations further support the link between the alter-
ation of cyclin-CDK complexes, loss of genomic integrity, and
neoplastic transformation.
Cyclin D complexes. Since its discovery, the function of
cyclin D1 has been the focus of many studies and still remains
elusive. Among all cell cycle regulators, cyclin D1 is the most
strongly implicated in oncogenesis (see reviews by Lammie and
Peters [31] and Motokura and Arnold [39]; 27, 35). D cyclins
differ from other members of cyclin family in several distinct
ways. They associate with virtually all CDKs, albeit with a
strong preference with CDK4. Expression of individual mem-
bers of the D cyclins is cell type and tissue specific, and the
level of cyclin D, both message and protein, does not signifi-
cantly oscillate during the cell cycle in many cell types as with
other cyclins. The cyclin D-associated kinase activity clearly
has a substrate specificity different from those of other cyclins,
with the majority of activity for cyclin D-CDK4/6 being de-
tected with the Rb protein and its relatives (14, 30, 37, 38).
Analysis of cyclin D complexes in cells expressing the indi-
vidual HPV oncogenes revealed further differences between D
cyclins and other cyclins. First, identical to fully transformed
cells, the cyclin D1-CDK4 and cyclin D1-CDK2 binary associ-
ations are dramatically reduced in cells expressing E6 and
totally disrupted in cells expressing E6 together with E7, while
other cyclin-CDK binary associations (e.g., cyclin B1-CDC2
and cyclin A-CDK2) remain largely intact in both cell types
(Fig. 6). We interpret the reduction of cyclin D-CDK binary
association in E6-expressing cells as the result of decreased
expression of p21 that has been implicated in stabilizing cyclin-
CDK complexes (23, 55). As in the fully transformed cells (54),
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cyclin D-CDK complexes are further reduced to nearly com-
plete absence in cells expressing both the E6 and E7 viral
oncoproteins, most likely as the result of the combined effects
of reduced p21 and activated p16 gene expression. We have
recently demonstrated that the transcription of p16 is re-
pressed by Rb, forming a regulatory feedback loop involving
Rb, CDKs, and p16 (33). According to this mechanism, phos-
phorylation of Rb by cyclin D-CDK4 or cyclin D-CDK6 results
in the release of a transcription factor (e.g., E2F-1) which is
inactive when bound to hypophosphorylated Rb. Disassocia-
tion of the RB-transcription factor complex, through Rb phos-
phorylation by CDK or inactivation by viral oncoproteins such
as HPV16 E7, would then activate p16 transcription. As levels
of p16 mRNA increase, increased binding of p16 to CDK4 and
CDK6 would prevent cyclin D from binding to CDK4 and
CDK6 and subsequent degradation. In addition to phosphory-
lating and controlling the activity of Rb and the related p107
and p130 proteins, cyclin D may be involved in the regulation
of such additional checkpoints as PCNA-dependent DNA re-
pair and replicative synthesis (45). Therefore, complete disso-
ciation and thus functional inactivation of cyclin D-CDK com-
plexes by the expression of E6 together with E7 may also
impair other, as yet unidentified cyclin D-mediated growth
control pathways.
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